These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24696308)

  • 21. Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease.
    Granoff DM
    Pediatr Infect Dis J; 2013 Apr; 32(4):372-3. PubMed ID: 23263177
    [No Abstract]   [Full Text] [Related]  

  • 22. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075-9.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6835; author reply 6835-6. PubMed ID: 17875437
    [No Abstract]   [Full Text] [Related]  

  • 24. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
    Su EL; Snape MD
    Expert Rev Vaccines; 2011 May; 10(5):575-88. PubMed ID: 21604979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MenB candidate vaccine Bexsero induces robust immune response in infants.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Mar; 8(3):282. PubMed ID: 23213659
    [No Abstract]   [Full Text] [Related]  

  • 26. Pfizer’s men B vaccine shows promise in phase 2.
    Hum Vaccin Immunother; 2012 Aug; 8(8):1016-7. PubMed ID: 23359878
    [No Abstract]   [Full Text] [Related]  

  • 27. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 28. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Authors' response: Meningococcal vaccine antigen diversity in global databases.
    Brehony C; Hill DM; Lucidarme J; Borrow R; Maiden MC
    Euro Surveill; 2016 Apr; 21(15):. PubMed ID: 27104935
    [No Abstract]   [Full Text] [Related]  

  • 30. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M
    N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
    Sanders H; Feavers IM
    Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of serogroup B meningococcal disease.
    Stephens DS
    Lancet; 2012 Feb; 379(9816):592-4. PubMed ID: 22260987
    [No Abstract]   [Full Text] [Related]  

  • 34. Vaccines Against Meningococcus - An update of the progresses in meningitis prevention. Proceeding of the Meningococcus Scientific Exchange Meeting. Siena, Italy. July 1-3, 2008.
    Vaccine; 2009 Jun; 27 Suppl 2():B1-125. PubMed ID: 19771612
    [No Abstract]   [Full Text] [Related]  

  • 35. Emerging clinical experience with vaccines against group B meningococcal disease.
    Wilkins AL; Snape MD
    Vaccine; 2018 Aug; 36(36):5470-5476. PubMed ID: 28778616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
    Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
    Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Meningococcal serogroup B vaccines].
    Dommergues MA
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.
    Nissen MD; Marshall HS; Richmond PC; Jiang Q; Harris SL; Jones TR; Jansen KU; Perez JL
    Pediatr Infect Dis J; 2013 Apr; 32(4):364-71. PubMed ID: 23114369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.
    Oster P; O'Hallahan J; Aaberge I; Tilman S; Ypma E; Martin D
    Vaccine; 2007 Apr; 25(16):3075-9. PubMed ID: 17289223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.